Continuous Glucose Monitoring is making a big impact on diabetes care – and patient outcomes. Learn more about the practicalities of bringing CGM into your practice and making it work for your staff, your colleagues, and your patients. At the end of the presentation, participants will be able to:

1. Prepare the clinical practice for CGM. 
2. 2Understand options available to the practice for professional and personal CGM. 
3. Locate and interpret CGM data, using the Ambulatory Glucose Profile (AGP) to assess if the patient is achieving targets established by the International Consensus on Time in Range. 
4. Modify the treatment plan based on CGM data to improve patient outcomes.

Obesity is a complex, multifactorial chronic condition. Forty percent of US adults are living with obesity. It has been correlated with 6 of the 10 top causes of death in industrialized nations and impacts the lives of 2 of every 3 patients a PA will see. Stigma against fat individuals impacts health outcomes and must be addressed to successfully care for all our patients.  At the end of this activity, participants will be able to:  

1. Discuss prevailing evidence about the clinical treatment of obesity 
2. Define obesity stigma and discuss its impact on health outcomes for fat patients
   1. Identify evidence-based best practices for treating obesity while destigmatizing care

The vast majority of primary care practitioners treat patients with pain. Acute pain is generally understood to have a specific cause, frequently injury or surgery, and can often resolve itself when underlying causes are addressed, usually in less than six months. That said, when left untreated, or treated outside of established guidelines, acute pain can easily turn into chronic pain, lasting years or more. Opioids had, until recent years, been the most-prescribed treatments for acute pain, and while clearer understandings of the dangers of opioid misuse and abuse have led to fewer prescriptions of this class of drugs, prescribers have been less aware of current guidelines for recommended therapies, including opioid agonists and non-steroidal anti-inflammatory drugs (NSAIDs).  At the end f this lecture, attendees will be able to: 

1. Recognize and diagnose acute pain. 
2. Understand the history and challenges of acute pain management. 
3. Use newer therapies for acute pain management.

This is a review of STI presentations and treatments.  At the end of this lecture, attendees will be able to:

1. Identify five most commonly diagnosed STIs in the US (chlamydia, trichomoniasis, HSV, HPV, gonorrhea.
2. Review risk factors for and presentation of these STIs.
3. Apply screening guidelines for these STIs. 
4. Apply current treatment guidelines of these STIs. 
5. Locate resources for monitoring screening and treatment guidelines. 

This lecture will consider the physiology of menopause, indications and contraindications for pharmacologic management, and treatment modalities. At the conclusion of this presentation, the attendee will be able to:

1. Discuss the significance of the Women's Health Initiative on the approach to management of menopausal symptoms.
2. List contraindications to hormonal treatment of menopausal symptoms.
3. Describe hormonal and non-hormonal methods of management of menopausal symptoms.

Thirty Million Americans, and 400 million people world wide have COPD.  Yet half of them have never been diagnosed.  How can this be the 3rd most common chronic condition, 3rd leading cause of admission, and 3rd leading cause of death, ... yet be hidden in plain site.  Healthcare providers on the front lines have the opportunity to ask the question, 'Could this be COPD?', and crack the code on the invisible epidemic.  At the end of this activity, learners will be able to: 

1. Recognize patients at high risk for COPD
2. Iidentify screening tools and methods to confirm their index of suspicion.
3. Lead a 'find the missing millions' in their place of service.
4. Advise patients where they should or could go next for confirmatory testing, and more information.
5. Identify social determinants of health that predispose patients to the risk of COPD.